This poster presents a financial assessment of hypothermic oxygenated perfusion (HOPE) in liver transplantation, using data from a U.S. randomized clinical trial comparing HOPE after static cold storage (SCS) to SCS alone. The analysis showed that HOPE-treated allografts resulted in fewer postoperative complications (especially biliary complications and graft failure requiring retransplantation), shorter hospital stays, and significant cost savings per transplant. The cost savings were most sensitive to changes in biliary complication rates and applied to transplants using extended criteria donors, including DCD livers. The study concluded that implementing HOPE can decrease costs associated with post-transplant complications and increase hospital revenues by expanding transplant capacity and reducing staff overtime.
Axelrod DA, Reich D, Schnitzler M. Economic Benefit of Hypothermic Oxygenated Liver Perfusion. Poster presented at: American Transplant Congress; June 2-5, 2024; Philadelphia, PA
